Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Study of SPD8-P vs Reference Biologic in Postmenopausal Women with Primary Osteoporosis
jRCT2031260369Phase 3Active, not recruiting
- Sponsor
- GlycoNex
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SPD8-P in involutional osteoporosis (2 arms), sponsored by GlycoNex. Primary endpoint: Percent change from baseline in lumbar spine BMD (L1–L4) at Week 52. Started Dec 2024; status: active, not recruiting.
02
Drugs
SPD8-P
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCT2031260369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260369.